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Purpose/Objective: SBRT treatment processes are complex 
and at risk of incidents/accidents due of the use a high 
dose/high precision treatment session. Our objective was to 
identify prospectively the risk of incident/accident at the 
time of deployment of SBRT within our radiotherapy 
department. 
Materials and Methods: Risk Analysis (RA) of SBRT was 
performed using the Failure Mode and Effects Analysis (FMEA) 
methodology and an existing chart review on 'consultation' 
and 'RT precription' for IMRT/IGRT which was updated by a 
multidisciplinary team (Physician, Physicist, Quality manager, 
Dosimetrist, RTTechnician). The risk level of various steps 
within the risk matrix was re-stated, using the classical 
scoring system taking into account the product of Probability, 
Severity and Detection. Corrective actions were then 
proposed when the risk level was deemed inacceptable. 
Results: Only a few risk levels were found higher due to the 
implementation of SBRT within the 'consultation' and 'RT 
prescription' flow-chart (mainly for steps concerning side 
effects and premedication supposed to prevent them) but 
their scores remained tolerable and were discussed within 
our multidisciplinary team. Of notice was the risk level of 
one step concerning the input of SBRT prescription (dose, 
fractionation, timing) in the dosimetry system though: the 
corresponding score rose significantly, as compared to 
IMRT/IGRT, reaching 45 and was deemed inacceptable ( 36 or 
more), requiring an immediate corrective action. The side of 
the volume to-be treated was also critical (score of 30) and 
was to be adressed by the same corrective action. The 
possible causes for those failure modes were essentially 
human errors. Our multidisciplinary team made the decision 
to implement a 'never-event' check list allowing a cross-
control of the treatment parameters by a dosimetrist and a 
physician altogether before the validation of dosimetry. A 
new round of grading will then be performed within 3 months 
in order to evaluate the impact of our corrective actions on 
risk-levels. Results will be shown at the meeting. 
Conclusions: Inacceptable risk levels through the treatment 
process were identified using RA based on the FMEA 
methodology. Where and when human errors could yield to a 
radiotherapy accident, a proper 'never-event' check-list was 
designed to deter the risk to the patient. The impact of this 
corrective action on risk-levels will be shown at the meeting. 
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Purpose/Objective: The purpose of this study is to quantify 
and compare different dose-volume constraints for the organs 
at risk (OARs) in breast cancer radiotherapy treatment for 
whole breast irradiation (WBI) without boost, and breast with 
simultaneous integrated boost (SIB). 
Materials and Methods: 54 breast cancer patients were 
evaluated. Studies were grouped regarding the type of 
treatment. The fractionation scheme was 2.0 Gy per fraction 
for WBI only and 2.4 Gy per fraction for SIB. Treatment 
planning was carried out using XiO TPS. Two tangential 
beams with field in field technique were used. 
The following parameters were recorded and evaluated for 
both treatment schemes:  
-Both lungs (considered as a single OAR): Dmean (mean 
dose), V5Gy, and V20Gy 
-Ipsilateral lung: Dmean, V5Gy, V20Gy 
-Heart: Dmean, V25Gy 
-Contralateral breast: Dmax, V10Gy 
-Gantry angles were also recorded as a possible independent 
influence variable. 
 
Results: 
 
Dmean for the heart is practically the same for both 
treatments. For the ipsilateral lung, Dmean, V5Gy and V20Gy 
are slightly higher in the case of SIB treatment. The same 
occurs for both lungs. 
The significance of these differences has been tested, with a 
5% significance level. The results and the p-value are shown 
in the Table 1. The differences are statistically significant for 
the lungs. 
In the contralateral breast the only differences are in the 
maximum dose. In both treatments, for the right cases this 
dose is higher than for the left cases. The gantry angles for 
the right cases are, in average: 55,61o for the medial-lateral 
beam (ML) and 126,58o for the lateral-medial beam (LM). In 
the left cases: 51,09o for the ML and 132,70o for the LM 
(gantry angles have been made simmetrical in order to 
compare left and right cases). 
Conclusions: The results shown before have demonstrated 
that in the SIB treatment, the lung receives a higher mean 
dose, and larger V5Gy and V20Gy. Moreover, we can conclude 
that these differences between WIB and SIB are statistically 
significant. The differences are not statistically significant in 
the case of the heart. 
For the right side cases, in both type of treatments the 
contralateral breast receives more maximum dose. This could 
be because of the different beam arrangement used for these 
cases. In left breast cases, the beam arrangement has a 
strong dependency with the heart position. The p-value 
shows that the differences between the beam arrangement 
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for the left and right cases are statistically significant for the 
ML beam. 
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Purpose/Objective: 
Introduction: Following the publication of the randomized 
clinical trial 'Axillary Dissection vs No Axillary Dissection in 
Women With Invasive Breast Cancer and Sentinel Node 
Metastasis' by Dr. Armando E. Giuliano et al. and taking into 
account the experience of our hospital in selective sentinel 
node dissection SLND (we performed SLND in our institution 
for 13 years to 1490 patients, 20% of the cases resulted 
metastatic sentinel node and only 8% of this cases had 
involvement of other nodes in the lymphadenectomy) , The 
Breast Cancer Committee of our hospital approved the 
implementation of the protocol ACOSOG Z0011. 
Aim: The primary end point was to determine disease free 
survival, defined as the time from diagnosis to the first 
documented recurrence of breast cancer. Breast cancer 
recurrence was categorized as locoregional disease (tumor in 
the breast or ipsilateral supraclavicular, subclavicular, 
internal mammary, or axillary nodes) or distant metastases. 
These morbidities have been reported 
Materials and Methods: Inclusion criteria: adult women with 
histologically confirmed breast carcinoma , tumor size 5 cm 
or less (T1-T2), no palpable adenopathy, negative axilla 
evaluated by ultrasound, and SLN positive for metastatic 
breast cancer documented by or hematoxylin-eosin staining 
on permanent section. Women were ineligible if they had 3 
or more positive SLNs (they received axillary lymph node 
dissection in the second time) and patients candidates to 
mastectomy. All women received whole-breast opposing 
tangential-field radiation therapy and Axillary radiotherapy 
included levels I and II. Radiation therapy not include 
supraclavicular fossa and level III. The use of adjuvant 
systemic treatment was applied at the discretion of the 
treating multidisciplinary team. 
Results: From February 2011 to June 2014, 88 patients met 
the inclusion criteria and were selected for analysis. All 
patients had invasive breast carcinoma and 1 or 2 sentinel 
node metastasis. Median follow-up was 24 months (5 – 39 
months). The average tumor size was 1.81 cm (0.6 to 3.7 
cm). Median excised lymph nodes was 2 and the median 
sentinel node with metastasis was 1. Breast cancer subtype 
was: Luminal A 42,2%, luminal B her2 – 35,6%, luminal B her2 
+ 8,9% Triple negative 8,9% , Her2 + no luminal: 4,4% 
At a median follow-up of 2 years disease-free survival was 
93.2%. 
Conclusions: In patients with limited SLN metastasis, breast 
cancer treatment with breast conservation, systemic therapy 
and radiation therapy, the use of SLND alone, avoiding the 
lymphadenectomy, provides good local control. 
Although, the results of this study are limited by the short 
follow up, we report our experience and working procedures 
to establish the ACOSOG Z0011 protocol in our center. 
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Purpose/Objective: Malignant tumors typically metastasize 
to lymph-nodes. These localizations can arise with associated 
symptoms or can be, in most cases, asymptomatic. Often 
node metastases can be the only site of active disease. It is 
reasonable to treat local metastasis with ablative therapies. 
Some evidence show that local ablative treatment can 
achieve a good response and an optimal local-disease control 
(LC). The aim of this study was to evaluate the feasibility, 
local control and the potential impact on survivals of 
stereotactic body radiotherapy in lymph-node metastases in 
oligometastatic patients. 
Materials and Methods: Fifty-eight patients with 66 lymph-
node metastases (32 male, 26 female) were treated with 
SBRT between 2009 and 2014. Site of node metastases were 
as follows: 38 (57,5%) intra-thoracic metastases, 28 (42.5%) 
abdominal/pelvic metastases. The most common primary site 
of tumor was lung 22 (38%), followed d by colon-rectum 7 
(12%) prostate 6 (10%), stomach 5 (9%), uterus 4 (7%), ovary 4 
(7%), breast 2 (3%), melanoma 2 (3%), and others (2%). Single 
fraction of 30Gy (24%) or 23Gy (26%) was used in 33 lymph 
nodes. Fractionated schedule was used for the other 33 
lymph node metastases. Variables was evaluates as 
prognostic factors. 
Results: Of the 66 pathological nodes response was achieved 
as follows: 37 nodes achieved complete response (56.2%), 
and 17 nodes achieved partial response (25.6%), while 10 
lesions had stable disease (15.2%). The progressive disease 
was observed for only 2 lesions (3%) after SBRT. The observed 
local control was 93% at 2-years. Disease-free survival was 
42.5% at 1-year and 30% at 2-years. The 1-year and 2-years 
overall survival was 80% and 65.8%, respectively. The PTV 
volume (<20 cc) was significantly associated with better DFS 
(p=0.043) and OS (p=0.001), respectively. For the other 
variables no impact on survivals was calculated. 
Conclusions: Stereotactic body therapy is feasible and safe 
for the treatment of metastatic lymph-nodes inside the 
thorax or the abdominal-pelvic area. Also, this treatment is 
efficient in a selected population of patients presenting 
oligometastic disease. SBRT can be administered even in 
patients receiving systemic therapies without increasing 
toxicity rates. 
   
 
